VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)
VEGF ECC
1 other identifier
observational
20
1 country
1
Brief Summary
The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2006
CompletedFirst Submitted
Initial submission to the registry
March 31, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2014
CompletedFirst Posted
Study publicly available on registry
April 3, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedApril 3, 2014
March 1, 2014
7.8 years
March 31, 2014
March 31, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.
the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).
the day when conducting surgery (day 1)
Study Arms (1)
ECC patients
Extrahepatic cholangiocarcinoma patients treated by surgical treatment
Interventions
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Eligibility Criteria
Extrahepatic cholangiocarcinoma patients underwent surgical therapy
You may qualify if:
- Extrahepatic cholangiocarcinoma patients diagnosed through biopsy; two or more dynamic imagine with a diagnosis of Extrahepatic cholangiocarcinoma
- Child-Pugh A or B
- well preserved renal and hematopoietic Function
- receive surgical therapy
- achieve complete section accessed by contrast-enhanced CT
You may not qualify if:
- incomplete section
- remote metastasis
- Child-Pugh C
- combination with other hepatobiliary disease
- suffer from other tumors concurrently or in last five years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510000, China
Biospecimen
Cut tissue into small pieces (\~2 mm2)and wash in drops of saline (1x PBS). Place pieces individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial. Pour out excess LN2 from vial, then seal and keep in LN2 until freezer storage.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ming Kuang, MD
First Affiliated Hospital, Sun Yat-Sen University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD,PhD
Study Record Dates
First Submitted
March 31, 2014
First Posted
April 3, 2014
Study Start
July 1, 2006
Primary Completion
April 1, 2014
Study Completion
September 1, 2014
Last Updated
April 3, 2014
Record last verified: 2014-03